A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma

NCT00551252 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Mesothelioma

Interventions

DRUG: Imatinib mesylate plus Gemcitabine

Sponsor

Gruppo Italiano MEsotelioma